Literature DB >> 9816230

Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma.

B Bhardwaj1, J Klassen, N Cossette, E Sterns, A Tuck, R Deeley, S Sengupta, B Elliott.   

Abstract

Platelet-derived growth factor (PDGF) BB is secreted by most human breast carcinoma cells; however, only recently have PDGF beta receptors been demonstrated in malignant breast tissue. In the present study, the tissue localization of PDGF beta receptor expression was studied in human breast carcinoma and nonmalignant breast tissues stained using both immunofluorescence and immunoperoxidase techniques. We examined a total of 29 cases of breast carcinomas, which showed both in situ and invasive components. PDGF beta receptor staining was localized in the periepithelial stroma and was particularly intense in regions immediately adjacent to carcinoma in situ components in all tumors examined. A diffuse low level of PDGF beta receptor staining was seen throughout the stroma of eight nonmalignant breast tissues as well as of nonmalignant regions of tumor tissues. Image analysis was used to assess the coincidence of staining of PDGF beta receptor with epithelial or stromal cells in 13 of the 29 tumor tissues studied. Less than 5% of malignant ductal epithelium or myoepithelium showed PDGF beta receptor staining. Analysis with stromal cell type-specific markers indicated significant localization of PDGF beta receptor primarily within alpha smooth muscle actin-staining cells (32%) and vascular endothelial cells (41%) in the periepithelial stroma. PDGF beta receptor positivity was strongly associated with periepithelial stromal cells adjacent to the basement membrane surrounding regions of carcinoma in situ but was less intense in regions of invasive carcinoma where basement membrane was degraded. The absence of PDGF beta receptors on carcinoma cells and their presence in the surrounding stroma suggest a paracrine stimulation of adjacent stromal tissue by malignant epithelial cells in human breast tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816230

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

Review 1.  Receptor imaging in breast carcinoma: future prospects.

Authors:  C Van de Wiele; S Van Belle; G Sleghers; R A Dierckx
Journal:  Eur J Nucl Med       Date:  2001-06

2.  VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis.

Authors:  Jianying Dong; Jeremy Grunstein; Max Tejada; Frank Peale; Gretchen Frantz; Wei-Ching Liang; Wei Bai; Lanlan Yu; Joe Kowalski; Xiaohuan Liang; Germaine Fuh; Hans-Peter Gerber; Napoleone Ferrara
Journal:  EMBO J       Date:  2004-07-01       Impact factor: 11.598

3.  Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.

Authors:  Roisin M Connolly; Michelle A Rudek; Elizabeth Garrett-Mayer; Stacie C Jeter; Michele G Donehower; Laurie A Wright; Ming Zhao; John H Fetting; Leisha A Emens; Vered Stearns; Nancy E Davidson; Sharyn D Baker; Antonio C Wolff
Journal:  Breast Cancer Res Treat       Date:  2011-02-25       Impact factor: 4.872

4.  A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.

Authors:  Helen K Chew; William E Barlow; Kathy Albain; Danika Lew; Allen Gown; Daniel F Hayes; Julie Gralow; Gabriel N Hortobagyi; Robert Livingston
Journal:  Clin Breast Cancer       Date:  2008-12       Impact factor: 3.225

5.  In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells.

Authors:  Marion T Weigel; Linda Dahmke; Christian Schem; Dirk O Bauerschlag; Katrin Weber; Peter Niehoff; Maret Bauer; Alexander Strauss; Walter Jonat; Nicolai Maass; Christoph Mundhenke
Journal:  BMC Cancer       Date:  2010-08-09       Impact factor: 4.430

6.  Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer.

Authors:  Janna Paulsson; Tobias Sjöblom; Patrick Micke; Fredrik Pontén; Göran Landberg; Carl-Henrik Heldin; Jonas Bergh; Donal J Brennan; Karin Jirström; Arne Ostman
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

7.  Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.

Authors:  M Cristofanilli; P Morandi; S Krishnamurthy; J M Reuben; B-N Lee; D Francis; D J Booser; M C Green; B K Arun; L Pusztai; A Lopez; R Islam; V Valero; G N Hortobagyi
Journal:  Ann Oncol       Date:  2008-05-29       Impact factor: 32.976

8.  Impact of PINCH expression on survival in colorectal cancer patients.

Authors:  Jasmine Lööf; Johan Rosell; Charlotte Bratthäll; Siv Doré; Hans Starkhammar; Hong Zhang; Xiao-Feng Sun
Journal:  BMC Cancer       Date:  2011-03-22       Impact factor: 4.430

9.  Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors.

Authors:  Craig I Campbell; Roger A Moorehead
Journal:  BMC Cancer       Date:  2011-11-09       Impact factor: 4.430

10.  CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma.

Authors:  Béatrice Cambien; Peggy Richard-Fiardo; Babou F Karimdjee; Violette Martini; Bernard Ferrua; Bruno Pitard; Heidy Schmid-Antomarchi; Annie Schmid-Alliana
Journal:  PLoS One       Date:  2011-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.